Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
文献类型：期刊论文
| 作者 | Fang, Y.3; Pan, H.3; Shou, J.4; Hong, W.5; Yang, X.6 ; Zhu, D.7; Zhou, Y.8; Lan, F.1; Rao, C.9; Chen, J.2
|
| 刊名 | JOURNAL OF THORACIC ONCOLOGY
 |
| 出版日期 | 2021-03-01 |
| 卷号 | 16 |
| 关键词 | Anlotinib NSCLC anti-angiogenesis |
| ISSN号 | 1556-0864 |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| WOS记录号 | WOS:000631349602067 |
| 出版者 | ELSEVIER SCIENCE INC |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/121729]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 2.Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China 3.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China 4.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 6.First Hosp Jiaxing, Jiaxing, Peoples R China 7.Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China 8.Cent Hosp Lishui City, Lishui, Peoples R China 9.Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China |
| 推荐引用方式 GB/T 7714 | Fang, Y.,Pan, H.,Shou, J.,et al. Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16. |
| APA | Fang, Y..,Pan, H..,Shou, J..,Hong, W..,Yang, X..,...&Chen, J..(2021).Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study.JOURNAL OF THORACIC ONCOLOGY,16. |
| MLA | Fang, Y.,et al."Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study".JOURNAL OF THORACIC ONCOLOGY 16(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。